Description
Triple-negative breast cancers (TNBC) are one of the most difficult cancers to treat, as they lack the common receptor targets for current breast cancer chemotherapies. TNBC represents 15-25% of all breast cancers, and RSK represents a nove…
Amendment chain · 3 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $225,000 at start, $500,000 after amendment #2 (+$275,000).
- #02018-04-01$225,000
- #12018-10-11$350,000+$125,000
- #22019-01-11$500,000+$150,000
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2018-04-01(start date) | $225,000 | — | Triple-negative breast cancers (TNBC) are one of the most difficult cancers to treat, as they lack the common… |
| #1 amendment | 2018-10-11 | $350,000 | +$125,000 | Triple-negative breast cancers (TNBC) are one of the most difficult cancers to treat, as they lack the common… |
| #2 amendment | 2019-01-11 | $500,000 | +$150,000 | Triple-negative breast cancers (TNBC) are one of the most difficult cancers to treat, as they lack the common… |
Related records · 9
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 808104087)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 172-2020-2021-Q4-966130 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Innovation Assistance Program | $5,419 | FY2021 |
| 172-2020-2021-Q3-960440 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Innovation Assistance Program | $12,176 | FY2021 |
| 172-2020-2021-Q1-950245 | National Research Council Canada | Conseil national de recherches Canada · Innovation Assistance Program | $10,164 | FY2021 |
| 172-2019-2020-Q2-931368 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $481,596 | FY2020 |
Other recipients funded under "Industrial Research Assistance Program – Contributions to Firms" by National Research Council Canada | Conseil national de recherches Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 172-2025-2026-Q2-1034675 | Mediphage Bioceuticals, Inc. | FY2027 | $63,380 | FY2027 |
| 172-2025-2026-Q3-1037522 | OBKIO INC. | FY2026 | $50,000 | FY2026 |
| 172-2025-2026-Q3-1037889 | SERVICES DE DEVELOPPEMENT PROFESSIONELS SDP INC | FY2026 | $25,000 | FY2026 |
| 172-2025-2026-Q2-1034040 | Griffith Foods Limited | FY2026 | $54,880 | FY2026 |
| 172-2025-2026-Q3-1037273 | Apollo Machine & Welding Ltd. | FY2026 | $230,000 | FY2026 |
Cite as: Glassbox record view · Federal grants & contributions · 172-2018-2019-Q1-904717 · retrieved 2026-11-15.